Ellen Rose has served as our Senior Vice President, Corporate Affairs since December 2025, bringing deep experience leading integrated communication, investor relations and patient advocacy strategies for public biopharmaceutical companies during periods of transformation and clinical advancement. She has a proven track record of directing strategies that support corporate growth and strengthen reputation and has helped facilitate public offerings totaling approximately $750 million. Previously, she was Senior Vice President, Communications and Investor Relations at Lyell Immunopharma, a publicly traded CAR T-cell therapy company, where she led corporate communications and investor relations as a member of the executive leadership team. Before Lyell, Ms. Rose was Senior Vice President, Communications and Chief of Staff to the CEO at Prothena Corporation, plc., a publicly traded company advancing therapies for neurodegenerative and rare diseases. She held several positions of increasing responsibility at Johnson & Johnson, guiding global communications across multiple therapeutic areas, including a role as Communications and External Affairs Leader for Johnson & Johnson Innovation where she helped launch Johnson & Johnson Innovations centers in the U.S., Europe and Asia Pacific. Ms. Rose earned a B.A. in International Relations from Stanford University.
